PLoS ONE · 2013 · 26 citations · 29 references
MedicineOncologyOral PathologyCancer ImmunologyOral OncologyTumor ImmunologyMalignant NeoplasmsOral Cancer BiomarkersOral Cancer PrognosisOral Cavity CancerOral NeoplasiaSquamous Cell CarcinomaDisease-specific SurvivalHistopathological Tumor ClassificationMolecular Risk MarkersOral Cavity PathologyPrognostic Marker AssessmentPrognostic Marker EvaluationPrognostic Risk AssessmentSquamous Cell Carcinoma Histology
FAS/FASL altered expression may cause tumor protecting immunomodulation, with a direct impact on patient prognosis. FAS expression was studied in 60 squamous cell carcinomas of the oral cavity. FAS expression did not show a significant association with tumor histopathological characteristics, but was significantly associated with lymph node positivity. FAS expression was significantly associated with disease specific death and negative FAS expression was an independent risk factor, increasing risk 4 times when compared to positive expression. When FAS and FASL expression results were combined, we were able to define high, intermediate and low risk profiles. Disease-free and disease-specific survival were significantly correlated with FAS/FASL expression profiles. The high risk category was an independent marker for earlier disease relapse and disease-specific death, with approximately 4- and 6-fold increased risk, respectively, when compared to the low risk profile. Risk profiles based on FAS/FASL expression showed that high risk was significantly associated with increased disease relapse and death, as well as shorter disease-free or disease-specific survival. This categorization, added to patient clinical data, may facilitate the choice of therapy, minimizing treatment failure and increasing disease control.
29
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.4K citations
Peter G. Isaacson, Ahmet Doǧan, Stephen K. Price et al. · The American Journal of Surgical Pathology · 1989 · 1.9K citations
Medicine, Endocrinology, Pathology +13
Human lung carcinomas express Fas ligand.
G A Niehans, Thomas Brunner, Sandra Frizelle et al. · PubMed · 1997 · 396 citations · Full text
Life Sciences, Immunology, Oncology +17
Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer
Sug Hyung Lee, Min Sun Shin, Won Sang Park et al. · Oncogene · 1999 · 241 citations